Hemophilia B gene therapy with a high-specific-activity factor IX variant

L. A. George, S. K. Sullivan, Adam Giermasz, J. E.J. Rasko, B. J. Samelson-Jones, Jonathan M Ducore, A. Cuker, L. M. Sullivan, S. Majumdar, J. Teitel, C. E. McGuinn, M. V. Ragni, A. Y. Luk, D. Hui, J. F. Wright, Y. Chen, Y. Liu, K. Wachtel, A. Winters, S. TiefenbacherV. R. Arruda, J. C.M. Van Der Loo, O. Zelenaia, D. Takefman, M. E. Carr, L. B. Couto, X. M. Anguela, K. A. High

Research output: Contribution to journalArticle

216 Scopus citations

Abstract

BACKGROUND The prevention of bleeding with adequately sustained levels of clotting factor, after a single therapeutic intervention and without the need for further medical intervention, represents an important goal in the treatment of hemophilia. METHODS We infused a single-stranded adeno-associated viral (AAV) vector consisting of a bioengineered capsid, liver-specific promoter and factor IX Padua (factor IX-R338L) transgene at a dose of 5×1011 vector genomes per kilogram of body weight in 10 men with hemophilia B who had factor IX coagulant activity of 2% or less of the normal value. Laboratory values, bleeding frequency, and consumption of factor IX concentrate were prospectively evaluated after vector infusion and were compared with baseline values. RESULTS No serious adverse events occurred during or after vector infusion. Vector-derived factor IX coagulant activity was sustained in all the participants, with a mean (±SD) steady-state factor IX coagulant activity of 33.7±18.5% (range, 14 to 81). On cumulative follow-up of 492 weeks among all the participants (range of follow-up in individual participants, 28 to 78 weeks), the annualized bleeding rate was significantly reduced (mean rate, 11.1 events per year [range, 0 to 48] before vector administration vs. 0.4 events per year [range, 0 to 4] after administration; P = 0.02), as was factor use (mean dose, 2908 IU per kilogram [range, 0 to 8090] before vector administration vs. 49.3 IU per kilogram [range, 0 to 376] after administration; P = 0.004). A total of 8 of 10 participants did not use factor, and 9 of 10 did not have bleeds after vector administration. An asymptomatic increase in liverenzyme levels developed in 2 participants and resolved with short-term prednisone treatment. One participant, who had substantial, advanced arthropathy at baseline, administered factor for bleeding but overall used 91% less factor than before vector infusion. CONCLUSIONS We found sustained therapeutic expression of factor IX coagulant activity after gene transfer in 10 participants with hemophilia who received the same vector dose. Transgenederived factor IX coagulant activity enabled the termination of baseline prophylaxis and the near elimination of bleeding and factor use.

Original languageEnglish (US)
Pages (from-to)2215-2227
Number of pages13
JournalNew England Journal of Medicine
Volume377
Issue number23
DOIs
StatePublished - Dec 7 2017

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Hemophilia B gene therapy with a high-specific-activity factor IX variant'. Together they form a unique fingerprint.

  • Cite this

    George, L. A., Sullivan, S. K., Giermasz, A., Rasko, J. E. J., Samelson-Jones, B. J., Ducore, J. M., Cuker, A., Sullivan, L. M., Majumdar, S., Teitel, J., McGuinn, C. E., Ragni, M. V., Luk, A. Y., Hui, D., Wright, J. F., Chen, Y., Liu, Y., Wachtel, K., Winters, A., ... High, K. A. (2017). Hemophilia B gene therapy with a high-specific-activity factor IX variant. New England Journal of Medicine, 377(23), 2215-2227. https://doi.org/10.1056/NEJMoa1708538